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Summary 
Cytotoxic T lymphocytes (CTL) recognize class I major histocompatibility complex molecules 
complexed to peptides of eight to nine residues generated from cytosolic proteins. We find that 
CTL recognize, in vitro and in vivo, cells synthesizing a 10-residue peptide consisting of an 
initiating methionine followed by nine residues corresponding to a naturally processed determinant 
from influenza virus nucleoprotein (NP) (residues 147-155).  Addition of two COOH-terminal 
residues corresponding to NP residues 157 and 158 severely  reduced presentation of the endogenously 
produced peptide to CTL in vitro and in vivo. Extension of NH2 and COOH terminal flanking 
residues to include residues corresponding to NP residues 137-146 and 159-168 failed to increase 
the antigenicity of this peptide. Its presentation was greatly enhanced, however, by further extending 
the NH2 and COOH  termini to include all of the additional residues of NP. These findings 
indicate first,  that a naturally processed viral ligand (with an NHz-terminal Met) of a class I 
molecule contains sufficient information to access intracellular  class I molecules, and second, that 
flanking residues  can influence the processing and presentation of antigens to CTL. 
C 
TL recognize peptides of 8-10 residues complexed with 
MHC class I molecules (1-3).  Synthetic peptides pro- 
vided exogenously (4) bind to class I molecules at the plasma 
membrane  (5-7).  Proteins  synthesized  endogenously are 
processed within the cell, and the resultant peptides appear 
to bind class I molecules in an early exocytic compartment 
(6-9). 
Little is known about the process by which antigenic frag- 
ments are generated and delivered to dass I molecules. While 
evidence suggests that some proteolysis occurs in the cytosol 
(10-14), it is uncertain whether the final cleavage steps occur 
within the cytosol, or after determinants have entered the 
exocytic compartment. The specificity of proteolysis is also 
poorly appreciated. Although a protein might have many pep- 
tides able to bind class I molecules with high affinity, only 
a  fraction might be liberated by proteolysis in quantities 
sufficient to load enough class I molecules to activate T cells. 
Some flanking sequences might hinder production of anti- 
genic peptides, while others might render them sensitive to 
digestion into smaller,  nonantigenic fragments. 
Knowledge is also limited regarding the transport of pep- 
tides to the exocytic compartment (possibly the endoplasmic 
reticulum), where association with class I molecules is pre- 
sumed to occur.  Recent reports describe genes within the 
MHC encoding members of the "ABC" transporter protein 
family (15-18) that might perform this function. The pep- 
tide specificity of any such transporter molecule would be 
expected to be one of the critical factors in determining the 
pool of determinants that class I molecules are able to bind 
and transport to the cell surface for immune surveillance. It 
is uncertain whether the putative peptide pumps are able to 
transport minimal peptide determinants with high affinity 
for class I molecules, or whether flanking sequences are re- 
quired for efffcient transport. It is also possible that flanking 
sequences could inhibit transport of class I binding peptides. 
In the present study we have examined whether cells are able 
to properly process small antigenic peptides expressed in the 
cytosol, and have tested the effects of various flanking sequences 
on the processing of these peptides. 
Materials  and Methods 
Synthetic Peptides.  Peptides  (provided by Dr. John Coligan of 
the Biological  Resources  Branch, National Institute of Allergy  and 
Infectious Diseases [NIAID], Bethesda, MD) were synthesized  on 
peptide synthesizers  (9050; MiUigen/Biosearch,  Burlington, MA; 
and 430; ABI, Foster  City, CA). After HPLC purification,  sequences 
were confirmed using an ABI 477A peptide sequencer, and the 
masses were confirmed by fast atom bombardment (M-Scan Inc., 
West Chester, PA). 
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fectious stock was generated by growth of virus in the allantoic 
cavity of embryonated hen eggs. Virus concentration in hemag- 
glutinating units was determined by chicken red cell agglutination 
(19). The PR8 NP, PR8 hemagglutinin (HA), and basic polymerase 
2 (PB2) vaccinia  virus (Vac) recombinants have  been described (20, 
21). Vac recombinants were generated as described  previously (22) 
with the following modifications. Minigenes were made by PCR 
of the PR8 influenza  virus NP cDNA (kindly provided  by Dr. Peter 
Palese, Mt. Sinai School of Medicine, New York, NY) using syn- 
thetic oligonucleotide primers containing restriction endonuclease 
sites (SalI in the upstream primer and NotI in the downstream 
primer) to enable directional ligation, the ATG initiation codon 
preceded by the sequence CCACC for efficient translation (23) in 
the upstream primer, and a double stop codon (TAGTGA) in the 
downstream primer. In each  primer, nonannealing  bases were flanked 
by 10 bases of fully annealing  sequence. PCR products were digested 
in Sail and NotI and inserted behind the Vac early-late PT.s pro- 
moter in a modified version of the pSC11 plasmid in which the 
restriction sites SalI and NotI were substituted for the SmaI site. 
The resulting constructs were then recombined into the wild-type 
vaccinia virus genome. The  NP/R-  gene was  constructed  as 
follows. PCR was used to generate two fragments coding for NP 
residues 1-159 and 149-498. Primers were designed to eliminate 
the Arg,s6 codon in both fragments, to effect a conservative  T to 
C change in the Alals3 codon, thereby generating a unique ApaI 
site in both fragments,  and to allow  cloning into the modified  pSC11 
vector described above. After treatment of the 1-159 fragment with 
Sall and ApaI, and the 149-498 fragment with ApaI and NotI, 
the two fragments were inserted into the modified  pSC11 plasmid. 
Sequencing of the gene (using the Sequenase kit from IBI, Inc., 
New Haven, CT) confirmed the loss of the Arg,~ codon, and also 
indicated a point mutation resulting in a Tyr3, to His313 substitu- 
tion. The M147-158/R-  and 137-168/R-  minigenes were made 
by PCR using as template the NP/R- gene and the same strategy 
described for generation of the M147-155 minigene. 
Northern Blotting.  10  s P815 cells were infected  with various Vac 
recombinants under the same conditions used in the CTL assays 
(described below). After a 5-h infection, cells were pelleted, washed 
with Dulbecco's PBS, and total RNA was extracted using R.NAzol 
B (Cinna/Biotecx Laboratories International, Inc., Friendswood, 
TX). RNA pellets were dissolved  in 0.2 ml H20, aliquoted, and 
either left untreated,  or incubated with RNase-free DNase or 
DNase-free RNase  (Boehringer Mannheim Biochemicals, Indi- 
anapolis, IN) with 10 mM CaCI: at 0.1 and 0.05/~g/ml,  respec- 
tively, for 30 min at 37~  Samples were then diluted 10-fold and 
adjusted to 7.5x  SSC, 4.9 M formaldehyde, and 0.1-ml volumes 
applied to nitrocellulose (BA-S 85 type; Schleicher  & Schuell, Inc., 
Keene, NH) mounted in a Minifold  II slot blot apparatus (Schleicher 
& Schuell, Inc.). The blot was dried under vacuum and probed 
using ~2p end-labeled oligonucleotides for the presence of RNA 
beating the 147-155 sequence (27 bases in length) or a sequence 
encoding the Vac complement binding protein early gene product 
(28 bases in length),  generously provided by Dr. Stuart  Isaacs 
(NIAID). 
CTL Assay.  P8t5 cells, serving  as APC in the assays,  were main- 
tained in RPMI  1640 with 7.5%  FCS at 37~  in an air/CO2 
(94%/6%) atmosphere. APC were infected for 1 h at 37~  with 
Vac recombinants at 10 PFU/cell at a concentration of 107 cells/ml 
in balanced salt solution with 0.1% BSA. Generally  2  x  106 APC 
1  Abbreviations used in this  paper: BFA, brefeldin A; HA, hemagglutinin; 
NP, nucleoprotein; PR8, A/Puerto Rico/8/34; Vac, vaccinia virus. 
were used for each infection. Afterwards, 10  ml IMDM  sup- 
plemented with 7.5% FCS was added, and the P815 cells were in- 
cubated an additional  3 h at 37~  with rotation. Cells were pelleted, 
suspended at  5  x  107 cells/ml in IMDM with 50-100 #Ci of 
NaSlCrO4 (Amersham Corp.,  Arlington,  Heights,  IL), and in- 
cubated for I h at 37~  APC were then washed three times with 
DPBS, suspended  in IMDM, and combined with CTL populations 
(described below) in round-bottomed  plates at  104 APCs/well. 
The final  volume per well was 0.2 ml. APC and CTL were coin- 
cubated for 4 h at 37~  before supernatants were collected (0.1-ml 
volumes) and counted in a gamma detector (5010 Cobra; Packard 
Instrument Co., Inc., Downers Grove, IL). The data are presented 
as percent specific SlCr, defined as follows: 100x [(experimental 
cpm  -  spontaneous cpm)/(total  cpm  -  spontaneous cpm)]. 
Generation of CTL.  CTL populations were generated as de- 
scribed (20). Briefly, BALB/cByJ  mice (The Jackson Laboratory, 
Bar Harbor, ME) were injected intravenously  with 107 PFU of Vac 
recombinants in 0.5 ml of DPBS. After at least 2 wk, splenocytes 
were harvested and coincubated with splenocytes  from naive mice 
that had been infected with PR8 or a Vac recombinant. Cultures 
were harvested after 6 or 7 d of incubation at 37~  and used in 
the CTL assays as described above. 
Results 
Presentation of the Endogenous  Peptide.  Recent work has 
shown that mouse H-2K  a molecules derived from influenza 
virus-infected cells are complexed to a major species of anti- 
genically active peptide derived from the viral nucleoprotein 
(NP), consisting of residues  147-155  (TYQRTRALV) (3). 
To examine the antigenicity of this peptide when originating 
in the cytosol of APC, a minigene (12) encoding the 147-155 
determinant  was  inserted  into  the  Vac  genome  (termed 
M147-155  Vac). Although it was necessary to add an NHz- 
terminal Met to initiate translation, it is likely that Met is 
effciently removed posttranslationally by Met-amino pepti- 
dase, since the penultimate residue is Thr (24). The antige- 
nicity of the peptide synthesized endogenously was first ex- 
amined by testing the lysis of Vac-infected APC by NP-specific 
CTL.  Table  1 A  shows  that  cells  infected with  the  Vac 
recombinant-encoding peptide M147-155  were lysed by NP- 
specific  CTL  as  efficiently as  cells  infected  with  a  Vac 
recombinant-expressing  full-length NE The specificity of rec- 
ognition was demonstrated by the low levels of lysis obtained 
using CTL specific for another viral gene product (HA) rec- 
ognized in association with K d (25)  (Table 1 A). 
It was important to demonstrate that the peptide was acting 
as a true endogenous antigen and not sensitizing APC by 
an exogenous route. Cells were treated with brefeldin A (BFA), 
an agent that blocks the presentation of antigens processed 
from  the  cytosol while  not  affecting presentation  of ex- 
ogenously added peptides (6, 7). BFA completely inhibited 
presentation of the M147-155 Vac-produced  peptide, while 
having no effect upon presentation of exogenous peptide (Table 
1 A, BFA). This is not simply due to inhibition of peptide 
biosynthesis, since reversal of the BFA blockade in the pres- 
ence of protein synthesis inhibitors to prevent additional pep- 
tide biosynthesis completely restored presentation (BFA Re- 
verse).  This  strongly  suggests  that  the  endogenously 
synthesized peptide  associates  with K a in  an intracellular 
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Percent  specific S~Cr release by CTL specific for:* 
P815 APC  A/PR8  Vaccinia 
infected/treated  with:  influenza  NP  HA  virus 
A 
B 
C 
M147-155 Vac  55  53  80  62  11  8  75  60 
M147-155 Vac BFA  0  0  3  2  0  0  0  0 
M147-155 Vac BFA reverse  52  51  73  66  4  6  76  62 
147-158/R-  peptide  33  31  50  35  0  0  0  0 
147-158/R-peptide  BFA  27  27  49  35  0  0  0  0 
NP Vac  51  53  66  58  16  11  86  69 
HA Vac  50  42  4  3  55  46  76  63 
M147-158/R-  Vac  7  6  7  4  9  1  84  72 
M147-158 Vac  44  41  60  51  13  9  78  61 
137-168/R-  Vac  12  8  3  1  7  1  71  55 
NP/R-Vac  43  39  56  53  13  6  67  47 
* Values for PIL8-, NP-, and HA-specific  slCr release are from CTL/APC ratios 30:1 and 10:1; for Vac-specific  SlCr release, values shown are from 
ratios 3.3:1 and 1.1:1. 
compartment.  It also demonstrates  that  the effect of BFA 
on antigen presentation  occurs independently of any effect 
it  might  have on intracellular  proteolysis. 
M147-155 Vac was further tested for its ability to prime 
splenocytes for secondary in vitro NP-specific responses  to 
PR8. The NP-specific CTL response generated was similar 
in magnitude to that observed with PR8-restimulated spleno- 
cytes derived from mice primed with NP-Vac (Table 2, Exp. 
A). Thus, the endogenously synthesized peptide was ef~dently 
presented  to T  cells  in vivo. 
Flanking Sequences Can Negatively Influence Presentation of 
the 147-155 Determinant.  To examine the effects of flanking 
Table  2.  Ability of the Endogenously Produced Peptides to Prime Mice  for a NP-specific Response 
Percent  specific SlCr release by APC treated with:* 
NP  147-158/K-  NP/K-  HA 
Exp.  Priming  Kestimulation  Vac  peptide  Vac  Vac 
A  M147-155 Vac  PK8  57  44  43  32  59  47  3  0 
NP Vac  PK8  66  58  49  35  56  53  4  3 
HA Vac  PR8  16  11  0  0  13  6  55  46 
B  M147-158/K-  Vac  PR8  22  15  11  5  20  9 
HA Vac  82  67  0  0  77  64 
M147-158 Vac  PK8  56  47  55  34  31  16 
NP Vac  PK8  58  39  63  35  9  3 
HA Vac  PR8  14  6  0  0  58  38 
PR8  HA Vac  24  9  0  0  48  28 
* For CTL populations generated by priming with a recombinant Vac and stimulating with a recombinant Vac, values shown are from CTL/APC 
ratios 3.3:1 and 1.1:1; all other values are from CTL/APC ratios 30:1 and 10:1. 
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ious minigenes encoding the 147-155  determinant within 
larger polypeptides were inserted into the Vac genome. Work 
by others has shown that the synthetic peptide representing 
amino acids 147-158 (TYQRTRALVRTG) is much less po- 
tent in sensitizing APC for lysis by NP-specific CTL than 
the 147-155 peptide (26). Remarkably, elimination from the 
147-158  peptide  of  the  Arg  at  position  156  (TYQK- 
TKALVTG) (147-158/R-)  was  observed to enhance sig- 
nificantly the potency of the synthetic peptide (26). Minigenes 
coding for the larger  147-158  and  147-158/R-  peptides, 
again with initiating Met residues, were inserted into the Vac 
genome (termed M147-158  Vac and M147-158/K-  Vac, 
respectively). Each virus was tested for its ability to sensitize 
APC for lysis by NP-specific CTL, and to prime mice for 
a NP-specific response. M147-158  Vac was effective in both 
respects  (Tables i  B  and 2,  Exp.  B).  M147-158/R-  Vac, 
however, did not sensitize APC for lysis by NP-specific APC 
and was minimally active in priming mice for a NP-specific 
response (Table 1 B and Table 2, Exp. B). Adequate infection 
of APCs by M147-158/R-  Vac was verified by the high de- 
g-tee oflysis by Vac-specific  CTL (Table 1 A). Adequate priming 
of mice with the recombinant was demonstrated  by high anti- 
Vac CTL activity after in vitro restimulation with a recom- 
binant Vac but not PK8 (Table 2, Exp.  B).  Northern blot 
analysis demonstrated that levels of minigene mKNA were 
similar in cells infected with all three recombinants (Fig. 1). 
Sequencing of genomic DNA from the recombinants con- 
firmed that each virus contained the proper gene in the cor- 
rect orientation. A second M147-158/K-  Vac constructed 
using an alternative strategy (synthetic oligonucleotides uti- 
lized in place of PCK products) gave similar results in sen- 
sitizing and priming (not shown). Thus, the poor antige- 
nicity of M147-158/K  Vac  is  likely to  reflect  inefficient 
processing of the peptide and not other factors. 
Flanking  Sequences Can Positively Influence the Presentation 
of  an Endogenous  Peptide.  To investigate whether the 147-158/ 
R-  sequence could be processed from intact NP for presen- 
tation to CTL, we produced a Vac recombinant encoding 
the full-length NP with Argls6 deleted (NP/R-  Vac) (see 
Materials  and Methods).  APC infected with NP/K-  Vac 
were efficiently lysed by YP-specific CTL (Table 1 C). The 
antigenic  determinant  within  the  NP/R-  molecule was 
confirmed to be 147-155 since APC infected with NP/K- 
Vac were lysed by CTL generated by priming with M147-155 
Vac (Table 2, Exp. A). These findings indicate that the nega- 
tive effect of flanking residues on presentation of a T cell de- 
terminant can  be  overcome by extension of the  flanking 
residues. This was further explored by construction of a Vac 
recombinant  expressing  the  147-158/K-  core  with  10 
amino acids corresponding to the NP sequence added to the 
NHz and COOH termini (D7-168/K-  Vac). The resulting 
peptide (137-168/R-)  is  a precise  segment of NP/K-  as 
Met is the natural residue at position 137. Cells infected with 
this recombinant were no better recognized by NPospecific 
CTL than those infected with M147-158/K-  Vac (Table 1). 
Thus, restoration of the immediate amino acid residues sur- 
Figure 1.  Equal amounts ofmRNA encoding the 147-155 NP sequence 
are generated by the various Vac recombinants. Total RNA was extracted 
from uninfected P815 cells or cells infected for 5 h with Vac recombimnts 
expressing NP peptides or an unrelated influenza virus gene product (PB2). 
RNA was bound to nitrocellulose and probed for the presence of sequences 
encoding the 147-155 NP segment (top) or a Vac gene product  (bottom). 
The left-hand column is a 10-fold dilution of the material applied to the 
right-hand column. In the case of the M147-158/K- Vac infection, the 
identity of hybridizing sequences as KNA is demonstrated by sensitivity 
to RNase and resistance to DNase. The specificity of the nucleases was 
confirmed by digestion  of plasmid DNA. 
rounding the 147-158/K-  peptide in NP/R-  was not suf- 
ficient  to rescue presentation of the 147-155  determinant. 
Discussion 
Others have shown that endogenously synthesized pep- 
tides containing from 9 to 13 flanking residues are efficiently 
presented to CTL (12-14). Our findings indicate that the nat- 
urally processed determinant itself (with an initiating Met) 
contains sufficient information to be trafficked to the appro- 
priate exocytic compartment. This is consistent with the idea 
that the ultimate determinant of eight to nine residues is pro- 
duced in the cytosol.  It is also possible that the processing 
of 147-155 from fuU-length NP (and presumably NP/R-) 
results from the generation of larger peptides in the cytosol 
that are trimmed after  transport (27).  However, there are 
clearly limits to the kinds of larger peptides that would be 
active in this model, since M147-158/R-  and 137-168/R- 
were not recognized. 
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recognition by synthetic peptides but not by endogenously 
synthesized proteins containing the peptide sequence (28). 
In this case, however, it was uncertain whether this was due 
to deficiencies in antigen processing, or in the ability of any 
form of the peptide processed from the protein to associate 
with class I molecules in an intracellular environment. This 
limitation does not apply to our study since we identify a 
peptide that associates with class I molecules and show that 
addition of flanking sequences can destroy its antigenicity. 
Thus,  we can conclude that the antigenicity of a peptide 
capable of binding class I molecules can be influenced by extra- 
antigenic sequences. Related observations were made by Town- 
send et al. (30) who found that a blockade in antigen presen- 
tation associated with Vac virus infection, first described by 
Coupar et al.  (29), could be surmounted by altering extra- 
determinant  residues  in  a  manner  resulting  in  enhanced 
degradation  of the  protein.  It  is  unlikely that  a  similar 
phenomenon is responsible for our observations, since in ad- 
ditional experiments (unpublished) we observed no correla- 
tion between presentation of 147-155  and the stability of its 
carrier protein or peptides (both NP and NP/R-  were stable 
while all of the minigene products appeared to be rapidly 
degraded, based on our failure to detect them in competition 
RIAs using antisera raised to the 147-I58  or 147-158R- 
peptides). Del Valet al. (31) recently reported that an anti- 
genic determinant from a murine cytomegalovirus protein 
was not presented when placed into certain regions of a for- 
eign protein. This effect did not appear to be related to the 
overall stability of the protein and occurred in cells expressing 
the gene products either as a result of DNA-mediated trans- 
fection or recombinant Vac infection. Thus, extra-antigenic 
residues can influence presentation of CTL determinants in- 
dependently of a Vac infection. 
Further experiments are required to determine the mecha- 
nism by which flanking sequences influence the presentation 
of the 147-155 determinant. Any one or combination of the 
following could be involved in the negative effects of flanking 
sequences, any of which could be influenced by Vac infec- 
tion: (a) sequestration of the peptides on peptide binding pro- 
teins in the cytosol or exocytic compartment; (b) inability 
of peptide intermediates to be transported from the cytosol 
to the exocytic compartment; (c) inability of peptide inter- 
mediates to associate  with accessory molecules that might 
function to deliver peptides to class I molecules in the exo- 
cytic compartment; or (d) inability of cellular proteases to 
generate the antigenic peptide from the protein or longer 
peptide. 
Possibly the most striking finding in the present study is 
that addition of two amino acids to the 147-155 determinant 
abolishes its presentation as an endogenous antigen. The ob- 
servation that this peptide is extremely e~cient at sensitizing 
target cells when provided as an exogenous antigen might 
suggest that the endogenous peptide is not properly trans- 
ported to class I molecules from the cytosol. It was recently 
found, however, that the ability of exogenous 147-158/R- 
to sensitize target cells for CTL lysis depends on a protease 
present in FCS that converts the peptide to the highly eflicient 
147-155 peptide (L. A. Sherman, personal communication). 
Thus,  there is  no compelling reason  to  suspect  that  the 
M147-158/R-  peptide is not transported from the cytosol. 
Rather, the only firm conclusion that can be made at present 
is that neither P815 cells nor APC in vivo possess a similar 
cytosolic proteolytic activity. 
It has recently been reported that "contaminants" consisting 
of eight to nine residues can account for essentially all of the 
antigenic activity in preparations of synthetic peptides longer 
than eight or nine residues (32).  Thus, it is likely that the 
binding of the 147-158  peptide to K d relative to 147-155  is 
even less than the 1% value suggested by peptide titration 
experiments  (26).  In  this  case,  the  presentation  of  the 
M147-158 peptide would almost certainly require trimming 
of the  COOH-terminal  residues  and  perhaps  the  NH2- 
terminal Met as well. That the endogenous M147-158/R- 
peptide is presented at such a low efficiency suggests that 
the absence of Argls6 might negatively influence the activity 
of the trimming enzymes. 
The ability of cells to process NP/R-  efliciently for as- 
sociation  with  K d indicates  that  the  effect of negatively 
acting  flanking  sequences can be  overcome by additional 
flanking sequences. Restoration of the structure of NP is not, 
however, essential for the processing of the 147-155  deter- 
minant in  the context of 147-158/R-,  since addition  of 
flanking residues unrelated to NP at the COOH terminus 
greatly increases  the antigenicity of the 147-158/R-  pep- 
tide without enhancing its apparent stability (unpublished 
results). This latter observation is consistent with reports that 
placement of other CTL determinants into new protein con- 
texts can have little effect on their presentation (33,  34). 
Finally,  our findings indicate that minimal determinants 
expressed by infectious recombinant vaccines are able to in- 
duce CTL ef~ciently. This complements previous findings 
that immunization with synthetic peptides can induce CTL 
(35).  As flanking sequences can negatively affect the im- 
munogenicity of minimal determinants, recombinant vaccines 
might best utilize the naturally processed peptides. 
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